Clearmind Medicine details inaugural advisory board

Clearmind Medicine Inc. submitted a Form 6-K for September 2025, mainly to furnish a press release dated September 25, 2025.

Accepted by SEC EDGAR 09/25/2025 - 07:56 AM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Clearmind Medicine Inc. submitted a Form 6-K for September 2025, mainly to furnish a press release dated September 25, 2025. The release announces the company’s inaugural Scientific Advisory Board meeting, focused on advancing psychedelic-derived therapies, underscoring Clearmind’s emphasis on scientific guidance for its development efforts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Clearmind Medicine Inc. (CMND) report in this September 2025 Form 6-K?

Clearmind Medicine Inc. reports the furnishing of a press release dated September 25, 2025. The release announces its inaugural Scientific Advisory Board meeting aimed at advancing psychedelic-derived therapies, highlighting the company’s focus on formal scientific oversight of its research and development strategy.

What is the main purpose of Clearmind Medicine’s September 25, 2025 press release attached to the Form 6-K?

The attached press release announces Clearmind Medicine’s inaugural Scientific Advisory Board meeting. This meeting is intended to advance the company’s psychedelic-derived therapies by drawing on expert scientific input, signaling a structured advisory framework for guiding its future therapeutic development initiatives.

How is the Scientific Advisory Board referenced in Clearmind Medicine’s (CMND) Form 6-K?

The Form 6-K references a press release titled “Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies.” This indicates the company has organized its first formal advisory board meeting to support and guide its psychedelic-derived therapy programs.

What type of regulatory filing did Clearmind Medicine Inc. (CMND) submit for September 2025?

Clearmind Medicine submitted a Form 6-K, which is a report of a foreign private issuer. In this case, the filing primarily serves to provide investors with a copy of the company’s September 25, 2025 press release about its inaugural Scientific Advisory Board meeting.

Does Clearmind Medicine’s September 2025 Form 6-K include detailed financial results for CMND?

The Form 6-K described here focuses on attaching a press release about a Scientific Advisory Board meeting. It does not present earnings data or financial tables in the provided excerpt, centering instead on corporate and scientific governance developments around psychedelic-derived therapies.

Where is Clearmind Medicine Inc. (CMND) headquartered according to this Form 6-K filing?

Clearmind Medicine Inc. lists its principal executive offices at 101 – 1220 West 6th Avenue, Vancouver, British Columbia. This address reflects the company’s operational base as a foreign private issuer submitting its Form 6-K under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on September 25, 2025, titled “Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies”.

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.

	(Registrant)

Date: September 25, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR